Irinotecan hydrochloride

Catalog No.S5026 Batch:S502604

Technical Data

Formula

C₃₃H₃₉ClN₄O₆

Molecular Weight

623.14

CAS No.

100286-90-6

Solubility (25°C)*

In vitro

DMSO

100 mg/mL (160.47 mM)

Water

Insoluble

Ethanol

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution	2%DMSO 1 98%Corn oil	0.24mg/ml	Taking the 1 mL working solution as an example, add 20 μL of 12 mg/ml clear DMSO stock solution to 980 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	2% DMSO 1 40% PEG 300 2 5%Tween80 3 53%ddH2O	2.0mg/ml	Taking the 1 mL working solution as an example, add 20 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 530 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Irinotecan (CPT-11, (+)-Irinotecan) hydrochloride is an inhibitor of Topoisomerase I (Topo I) that exhibits cytotoxicity in LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

Targets

Topo I ^[1]	cytotoxicity in HT-29 cells ^[1] (Cell-based assay)	cytotoxicity in LoVo cells ^[1] (Cell-based assay)
	5.17 μM	15.8 μM

In vitro

The combination of gefitinib and irinotecan has a significant synergistic effect on the proliferation and migration of MDA-MB-231 cells.^[2]

In vivo

The combination of gefitinib and irinotecan has a significant synergistic effect in the treatment of TNBC subtype cells in xenograft model.^[2]

Protocol (from reference)

Cell Assay:^{^[2]}	Cell lines Human BC cell lines Concentrations 32 μM Incubation Time 24 h, 72 h Method Cells are seeded in 96-well plates at 6 × 103 cells/well for overnight incubation. The cells are exposed to irinotecan alone or combinations. Seventy-two hours after drug treatment, cell viability is tested with the MTT assay. For wound fealing assay, cells are seeded in 6-well culture plates at a density of 3 × 10⁵ cells/mL. After growing to confluence, cells are treated with irinotecan for 48 h in DMEM.

Cell Assay:^{^[2]}

Cell lines
Human BC cell lines
Concentrations
32 μM
Incubation Time
24 h, 72 h
Method
Cells are seeded in 96-well plates at 6 × 103 cells/well for overnight incubation. The cells are exposed to irinotecan alone or combinations. Seventy-two hours after drug treatment, cell viability is tested with the MTT assay. For wound fealing assay, cells are seeded in 6-well culture plates at a density of 3 × 10⁵ cells/mL. After growing to confluence, cells are treated with irinotecan for 48 h in DMEM.

References

Selleck's Irinotecan hydrochloride has been cited by 21 publications

Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer [ Drug Resist Updat, 2023, 71:101005]	PubMed: 37647746
A novel TOX3-WDR5-ABCG2 signaling axis regulates the progression of colorectal cancer by accelerating stem-like traits and chemoresistance [ PLoS Biol, 2023, 21(9):e3002256]	PubMed: 37708089
A novel TOX3-WDR5-ABCG2 signaling axis regulates the progression of colorectal cancer by accelerating stem-like traits and chemoresistance [ PLoS Biol, 2023, 21(9):e3002256]	PubMed: 37708089
HECW2 promotes the progression and chemoresistance of colorectal cancer via AKT/mTOR signaling activation by mediating the ubiquitin-proteasome degradation of lamin B1 [ J Cancer, 2023, 10.7150/jca.87545]	PubMed: 37781079
HECW2 promotes the progression and chemoresistance of colorectal cancer via AKT/mTOR signaling activation by mediating the ubiquitin-proteasome degradation of lamin B1 [ J Cancer, 2023, 14(15):2820-2832]	PubMed: 37781079
Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity [ Adv Sci (Weinh), 2022, e2201539]	PubMed: 35652270
Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines [ Cancers (Basel), 2022, 14(5)1230]	PubMed: 35267538
coupled Hydrodynamic Flow Focusing (cHFF) to Engineer Lipid-Polymer Nanoparticles (LiPoNs) for Multimodal Imaging and Theranostic Applications [ Biomedicines, 2022, 10(2)438]	PubMed: 35203647
K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications [ Dis Model Mech, 2022, 15-2dmm049004]	PubMed: 35174853
Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures [ Biomaterials, 2021, 280:121276]	PubMed: 34890975

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.